PAVmed Inc. Schedule 13G reports that the Craig Kallman 2015 Living Trust and Craig Kallman together beneficially own 384,616 shares of PAVmed common stock. The filing states this equals 6.0% of the class, based on 6,383,089 shares outstanding as of March 27, 2026.
The Trust holds sole voting and sole dispositive power over the 384,616 shares. The Reporting Persons filed a Joint Filing Agreement and note Mr. Kallman controls the Trust.
Positive
None.
Negative
None.
Insights
Ownership disclosure shows a significant 6.0% stake held via a family trust.
The filing identifies the Craig Kallman 2015 Living Trust and Craig Kallman as joint reporting persons with sole voting and dispositive power over 384,616 shares. The stake is calculated from 6,383,089 shares outstanding as of March 27, 2026.
Because the position is held in a trust controlled by Mr. Kallman, subsequent filings or amendments could clarify any changes; timing for any future transactions is not stated in the excerpt.
Key Figures
Shares beneficially owned:384,616 sharesPercent of class:6.0%Shares outstanding:6,383,089 shares
3 metrics
Shares beneficially owned384,616 sharesheld by Craig Kallman 2015 Living Trust (reported in Schedule 13G)
Percent of class6.0%percent of outstanding common stock based on provided share count
Shares outstanding6,383,089 sharesoutstanding as of March 27, 2026 per Form 10-K
"This is filed by the Craig Kallman 2015 Living Trust"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownsfinancial
"The Trust beneficially owns 384,616 shares of Common Stock"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
Joint Filing Agreementregulatory
"Reporting Persons have entered into a Joint Filing Agreement, a copy filed as Exhibit 99.1"
What stake does Craig Kallman hold in PAVmed (PAVM)?
Mr. Kallman and his Trust beneficially own 384,616 shares, representing 6.0% of PAVmed's common stock. This percentage is calculated from 6,383,089 shares outstanding as of March 27, 2026.
Does Craig Kallman have voting control over his PAVmed shares?
Yes. The Trust and Mr. Kallman each report sole voting power and sole dispositive power for 384,616 shares, meaning they control voting and disposition of those shares.
What document governs joint reporting for these holdings?
The Reporting Persons executed a Joint Filing Agreement, filed as Exhibit 99.1, under which they agreed to file Schedule 13G and any amendments jointly in accordance with Rule 13d-1(k).
How was the percent ownership calculated in the filing?
The 6.0% figure was calculated using 6,383,089 shares outstanding as of March 27, 2026, as stated in the company's Form 10-K filed the same date.
Are the shares held directly or through an entity?
The shares are held by the Craig Kallman 2015 Living Trust. Mr. Kallman may be deemed to beneficially own them because he controls the Trust, per the filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PAVmed Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
70387R502
(CUSIP Number)
03/27/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
70387R502
1
Names of Reporting Persons
Kallman Craig
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
384,616.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
384,616.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
384,616.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
70387R502
1
Names of Reporting Persons
Craig Kallman 2015 Living Trust
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NEW YORK
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
384,616.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
384,616.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
384,616.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PAVmed Inc.
(b)
Address of issuer's principal executive offices:
360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NEW YORK, 10017.
Item 2.
(a)
Name of person filing:
This Schedule 13G is filed by the Craig Kallman 2015 Living Trust ("Trust") and Craig Kallman ("Mr. Kallman," and together with the Trust, the "Reporting Persons"). Mr. Kallman controls the Trust. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 99.1 to the Schedule 13G, pursuant to which such Reporting Persons have agreed to file the Schedule 13G and all amendments thereto jointly in accordance with the provisions of Rule 13d-1(k) of the Act. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The principal business address of each of the Reporting Persons is 200 East 62nd Street, New York, New York, 10065.
(c)
Citizenship:
The Trust is a trust governed by the laws of New York. Mr. Kallman is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
70387R502
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The Trust beneficially owns 384,616 shares of Common Stock. Mr. Kallman may be deemed to beneficially own the shares of Common Stock held by the Trust, because Mr. Kallman controls the Trust.
(b)
Percent of class:
Each of the Trust and Mr. Kallman beneficially owns 6.0% of the outstanding shares of Common Stock. The percentage of beneficial ownership is calculated based on 6,383,089 shares of Common Stock outstanding as of March 27, 2026, as set forth in the Company's annual report on Form 10-K filed on March 27, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Trust: 384,616 shares
Mr. Kallman: 384,616 shares
(ii) Shared power to vote or to direct the vote:
Trust: 0 shares
Mr. Kallman: 0 shares
(iii) Sole power to dispose or to direct the disposition of:
Trust: 384,616 shares
Mr. Kallman: 384,616 shares
(iv) Shared power to dispose or to direct the disposition of:
Trust: 0 shares
Mr. Kallman: 0 shares
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
